China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)

China · Delayed Price · Currency is CNY

16.05

+0.02 (0.12%)

Sep 24, 2026, 3:00 PM CST

Market Cap	16.58B -13.9%
Revenue (ttm)	10.80B -2.7%
Net Income	1.61B +3.3%
EPS	1.56 +3.1%
Shares Out	1.03B
PE Ratio	10.29
Forward PE	9.39
Dividend	0.48 (2.98%)
Ex-Dividend Date	Jul 28, 2026

Volume	5,035,996
Open	16.02
Previous Close	16.03
Day's Range	15.94 - 16.11
52-Week Range	15.29 - 19.77
Beta	-0.08
Analysts	Strong Buy
Price Target	24.30 (+51.4%)
Est. Earnings	Oct 27, 2026

About SHA:600062

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People’s Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiar... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1939

Employees 13,184

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600062

Full Company Profile

Financial Performance

In 2025, SHA:600062's revenue was 11.00 billion, a decrease of -1.88% compared to the previous year's 11.21 billion. Earnings were 1.65 billion, an increase of 1.18%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 600062 stock is "Strong Buy." The 12-month stock price target is ¥24.30, which is an increase of 51.40% from the latest price.

Price Target

¥24.30

(51.40% upside)

Analyst Consensus: Strong Buy

Stock Forecasts